Technical Analysis for IGMS - IGM Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
29.08 | 3.60% | 1.01 |
IGMS closed up 3.6 percent on Friday, December 13, 2019, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| See historical IGMS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| NR7 | Range Contraction | 3.60% | |
| Wide Bands | Range Expansion | 3.60% | |
| Overbought Stochastic | Strength | 3.60% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Biotechnology Cancer Manufacturing Medical Specialties Immunology Treatment Of Cancer Antibodies Glycoproteins Protein Engineering Biochemistry
Biotechnology Cancer Manufacturing Medical Specialties Immunology Treatment Of Cancer Antibodies Glycoproteins Protein Engineering Biochemistry
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.7099 |
| 52 Week Low | 16.1 |
| Average Volume | 104,215 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 22.35 |
| 20-Day Moving Average | 23.88 |
| 10-Day Moving Average | 24.34 |
| Average True Range | 2.59 |
| ADX | 19.73 |
| +DI | 30.40 |
| -DI | 14.89 |
| Chandelier Exit (Long, 3 ATRs ) | 22.95 |
| Chandelier Exit (Short, 3 ATRs ) | 27.19 |
| Upper Bollinger Band | 29.56 |
| Lower Bollinger Band | 18.21 |
| Percent B (%b) | 0.96 |
| BandWidth | 47.52 |
| MACD Line | 1.24 |
| MACD Signal Line | 0.56 |
| MACD Histogram | 0.6761 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.35 | ||||
| Resistance 3 (R3) | 34.31 | 32.51 | 33.47 | ||
| Resistance 2 (R2) | 32.51 | 31.17 | 32.53 | 33.18 | |
| Resistance 1 (R1) | 30.79 | 30.34 | 31.65 | 30.84 | 32.89 |
| Pivot Point | 28.99 | 28.99 | 29.42 | 29.02 | 28.99 |
| Support 1 (S1) | 27.28 | 27.65 | 28.14 | 27.32 | 25.27 |
| Support 2 (S2) | 25.48 | 26.82 | 25.50 | 24.98 | |
| Support 3 (S3) | 23.77 | 25.48 | 24.69 | ||
| Support 4 (S4) | 23.81 |
